1 Min Read
Oct 31 (Reuters) - Daiichi Sankyo Co Ltd
* Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.